Aclaris Therapeutics Shares Spike Higher; Piper Sandler Upgrads Stock To Overweight With $13 Target Following Biosion Deal; Highlights Pipeline For Atopic Dermatitis And I&I Market, Catalysts Expected In 2025 Trials
Aclaris Therapeutics Shares Spike Higher; Piper Sandler Upgrads Stock To Overweight With $13 Target Following Biosion Deal; Highlights Pipeline For Atopic Dermatitis And I&I Market, Catalysts Expected In 2025 Trials
aclaris therapeutics股价大涨；派杰投资调升股票评级至超配，目标价为13美元，此举是在Biosion交易后进行的；突出展示特应性皮炎和I&I市场的产品线，2025年预期试验的催化剂
Aclaris Therapeutics Shares Spike Higher; Piper Sandler Upgrads Stock To Overweight With $13 Target Following Biosion Deal; Highlights Pipeline For Atopic Dermatitis And I&I Market, Catalysts Expected In 2025 Trials
aclaris therapeutics的股票大幅上涨；派杰投资将其评级上调至增持，目标价为13美元，此举是根据与Biosion的交易；强调了针对特应性皮炎和免疫炎症市场的产品管线，预计在2025年的试验中会有催化剂跟进。
资讯热榜
更新时间